1. Home
  2. LGND vs HASI Comparison

LGND vs HASI Comparison

Compare LGND & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • HASI
  • Stock Information
  • Founded
  • LGND 1987
  • HASI 1981
  • Country
  • LGND United States
  • HASI United States
  • Employees
  • LGND 68
  • HASI N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • HASI Real Estate Investment Trusts
  • Sector
  • LGND Health Care
  • HASI Real Estate
  • Exchange
  • LGND Nasdaq
  • HASI Nasdaq
  • Market Cap
  • LGND 3.2B
  • HASI 3.6B
  • IPO Year
  • LGND 1992
  • HASI 2013
  • Fundamental
  • Price
  • LGND $191.31
  • HASI $27.71
  • Analyst Decision
  • LGND Strong Buy
  • HASI Strong Buy
  • Analyst Count
  • LGND 8
  • HASI 6
  • Target Price
  • LGND $144.71
  • HASI $38.67
  • AVG Volume (30 Days)
  • LGND 139.7K
  • HASI 1.2M
  • Earning Date
  • LGND 08-05-2025
  • HASI 11-06-2025
  • Dividend Yield
  • LGND N/A
  • HASI 6.06%
  • EPS Growth
  • LGND N/A
  • HASI N/A
  • EPS
  • LGND N/A
  • HASI 1.59
  • Revenue
  • LGND $181,488,000.00
  • HASI $92,418,000.00
  • Revenue This Year
  • LGND $18.41
  • HASI $184.74
  • Revenue Next Year
  • LGND $18.87
  • HASI $13.79
  • P/E Ratio
  • LGND N/A
  • HASI $17.45
  • Revenue Growth
  • LGND 53.40
  • HASI N/A
  • 52 Week Low
  • LGND $81.74
  • HASI $21.98
  • 52 Week High
  • LGND $129.90
  • HASI $36.56
  • Technical
  • Relative Strength Index (RSI)
  • LGND 66.71
  • HASI 38.10
  • Support Level
  • LGND $182.87
  • HASI $27.72
  • Resistance Level
  • LGND $194.44
  • HASI $29.10
  • Average True Range (ATR)
  • LGND 5.79
  • HASI 0.80
  • MACD
  • LGND -0.38
  • HASI -0.24
  • Stochastic Oscillator
  • LGND 81.23
  • HASI 10.43

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: